The Drug Enforcement Administration will focus over the next 45 days on pharmacies and prescribers who are dispensing “unusual or disproportionate amounts” of prescription opioid drugs, Attorney General Jeff Sessions announced this week. “DEA collects some 80 million transaction reports every year from manufacturers and distributors of prescription drugs,” Sessions said. “These reports contain information like distribution figures and inventory. DEA will aggregate these numbers to find patterns, trends, statistical outliers – and put them into targeting packages. That will help us make more arrests, secure more convictions – and ultimately help us reduce the number of prescription drugs available for Americans to get addicted to or overdose from these dangerous drugs.” In August, Sessions announced the Opioid Fraud and Abuse Detection Unit, a new data analytics program focused on opioid-related health care fraud.

Related News Articles

Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
Eligible organizations can apply through May 6 for up to $1 million each for a three-year period to expand opioid and other substance use disorder services in…
Insights and Analysis
Birmingham VA Medical Center’s weekly, 90-minute shared medical appointments help veterans address opioid reliance.